GlaxoSmithKline Plc and Theravance Inc. April 28 announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder) now is available in the U.S.
The FDA approved the product in December 2013 for the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease 11 PLIR 1528, 12/20/13.
Under its 2002 collaboration agreement with GSK, Theravance agreed to make a milestone payment of $30 million to GSK after the launch of Anoro Ellipta. Theravance is based in South San Francisco, Calif., and GSK is based in the U.K.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.